Tag: CPI-444

April 26, 2018

Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced...
March 2, 2018

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced...
April 4, 2017

Corvus Presents Provisional Data On CPI-444

Corvus Pharmaceuticals shared interim data from an ongoing clinical study at the American Association for Cancer Research Annual Meeting.